Daily Market Reports | 10:30 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
360 AGN ALK AOV ARF ASK CBA EBR EVN GOZ IAG IFT LAM LGI LNW (2) MAP NAN ORA ORE ORG PLS PME (2) RHC S32 SGM SUN TAH TLS TPW (3) TWE VAU VGL (2) VNT WAF WBC
360 LIFE360 INC
Software & Services - Overnight Price: $43.34
Canaccord Genuity rates ((360)) as Buy (1) -
Canaccord Genuity assesses Life360's 2Q25 result as strong with monthly active users up 4.3m q/q to 88m. Average revenue per subscription rose 7.5% y/y, driven by higher-priced membership tiers and improved mix.
Revenue rose 36% y/y to US$115.4m, beating consensus by 5% and adjusted EBITDA was ahead of consensus due to higher margin.
Overall, the broker highlights the company is sustaining strong subscription momentum and scaling advertising, while hardware remains steady. The 2Q outcome drove a guidance upgrade across revenue and EBITDA for FY25, with margins tracking ahead of expectations.
FY25 adjusted EBITDA lifted by 9.6% and FY26 by 5.3%.
Buy. Target lifted to USD$90 (was US$86 on July 27).
This report was published on August 11, 2025.
Current Price is $43.34. Target price not assessed.
Current consensus price target is $47.63, suggesting upside of 9.9%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 EPS of 44.86 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 96.60.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 71.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 60.7.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 EPS of 77.35 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 56.03.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 109.5, implying annual growth of 53.4%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 39.6.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AGN ARGENICA THERAPEUTICS LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $0.73
Petra Capital rates ((AGN)) as Buy (1) -
Argenica Therapeutics' ARG-007 new drug application was put on hold by the US FDA in June and now it has required for additional data to resolve the clinical hold.
Petra Capital reckons the requests are straightforward, low-cost and unlikely to derail timelines, given US trial is not expected until mid-2026.
The broker views the real driver for the stock as the September Phase 2 Seancon stroke trial results, which could meaningfully de-risk ARG-007 and attract partnerships in a large underserved market. Balance sheet is sufficient to reach this catalyst.
FY25 EPS forecast lifted but FY26 trimmed on timing of opex and tax rebate impact.
Buy. Target rises to $1.22 from $1.19.
This report was published on August 15, 2025.
Target price is $1.22 Current Price is $0.73 Difference: $0.49
If AGN meets the Petra Capital target it will return approximately 67% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 4.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 16.98.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 4.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 15.53.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ALK ALKANE RESOURCES LIMITED
Gold & Silver - Overnight Price: $0.88
Moelis rates ((ALK)) as Buy (1) -
Moelis notes the highlight from Alkane Resources' exploration update for Tomingley gold project was the El Paso deposit where the results were variable but showed strong peak grades and thickness.
The Tomingley structure didn't reveal economic grades but did support potential for broader system scale, justifying follow-up drilling. The company is on track to deliver 170koz gold in FY26, the broker estimates.
The broker also commented on media report suggesting China's refusal to forward shipment to US customer, noting it suggests the strategic importance of antimony as a critical mineral.
Buy. Target unchanged at $1.15.
This report was published on August 14, 2025.
Target price is $1.15 Current Price is $0.88 Difference: $0.27
If ALK meets the Moelis target it will return approximately 31% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY25:
Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 5.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.44.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 13.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.57.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE